Welcome to Curium Driving innovation in nuclear medicine to improve patients’ lives

Curium is a global leader in nuclear medicine, with more than a century of expertise in the development, manufacturing and delivery of radiopharmaceuticals. Building on this heritage, we are advancing innovative radiodiagnostic and radiotherapy solutions to support better patient care.

Leading

global position

100+

years of trusted legacy

50+

nuclear medicine products

80+

manufacturing sites

45+

radiopharmacies

6000+

global customers

3800+

experienced colleagues

70+

countries

14m+

patients annually

100%

focus on nuclear medicine

1

molybdenum processing plant

€1bn

annual revenue in 2025

Home Stats Image

Headquartered in Boston, with operations and offices around the world, Curium is advancing nuclear medicine across both diagnostics and therapeutics, with a growing focus on targeted radiopharmaceutical therapies that have the potential to transform cancer care.

“My family's experience with cancer reminds me that behind every treatment is a person, a family, and a future worth fighting for.”

Ian Dietrich - Senior Process Engineer

“I'm motivated to keep pushing the boundaries of nuclear medicine because it makes such a difference to the patients and their families.”

Dr Amy Eccles, Radiologist

“Our operations team is really solution oriented and extremely persistent to overcome adversity”

Aurelie Gasse – Deputy General Manager, France

“I know that, like many others at Curium, I’m able to make a very direct impact on patients’ lives”

Gauthier de Noyelle – Strategy Senior Director, International

“Supporting patients at every step means turning our values into real care, real compassion, and real impact”

Eva Turkowiak, Sales and Marketing Manager DACH

Leading in product quality Delivering with heart

From potentially life-saving diagnostic solutions to vital therapies, Curium’s growing range of nuclear medicine solutions is designed with patients in mind and built on trust, quality and care at every step.

Disease areas
01
Supporting the diagnosis and management of cardiovascular diseases.
02
Advancing nuclear medicine solutions for endocrine and metabolic disorders.
03
Supporting the evaluation of gastrointestinal function and disease through precision imaging.
04
Providing nuclear medicine solutions for blood disorders and related cancers.
05
Helping detect and monitor infection and inflammatory disease with precision imaging.
06
Supporting liver and spleen imaging with specialised nuclear medicine solutions.
07
Advancing lymphatic imaging solutions for disease staging and treatment planning.
08
Enhancing the detection and monitoring of bone and joint conditions.
09
Supporting renal imaging and kidney function assessment through nuclear medicine.
10
Advancing brain imaging solutions for neurological disorders and diseases.
11
Delivering precision nuclear medicine solutions for cancer diagnosis and treatment.
12
Supporting lung imaging and respiratory assessment with advanced nuclear medicine solutions.
13
Providing reliable radionuclide generator technologies for diagnostic isotope production.
14
Supporting the diagnosis and treatment of rare diseases through specialised nuclear medicine solutions.
15
Supporting the evaluation of inflammatory and autoimmune musculoskeletal disorders.
16
Providing nuclear medicine solutions for the diagnosis and management of urological conditions.

Translating nuclear medicine science into new radiodiagnostics and radiotherapeutics

Collaboration drives innovation, bringing together expertise, science and shared ambition to advance patient care

Supporting independent research that expands knowledge, explores new possibilities and advances clinical practice

A curated collection of educational content, training and reference materials for healthcare professionals

Latest News, Events and Resources

Our global network Integrated and expansive

From isotope production to patient delivery, our integrated network spans continents to ensure timely, reliable access to nuclear medicine.